COVID-19

In this report by It’s Not Healthy, we analyze the main vaccines that exist globally, their origin, their financing, aspects related to intellectual property, purchase agreements and their different prices. We show how the origin of vaccines is in projects developed for decades with large contributions of public money and that this knowledge and investment, together with the one made in the pandemic, have been left in the hands of the industry without conditions and without ensuring universal access or fair prices for all countries. In addition, we reveal that production is mainly concentrated in rich countries, while factories in Asia, Latin America and Africa are being wasted, despite the production and distribution problems that the pharmaceutical industry has shown.

01/06/2021

The vaccine: a global public good to face a pandemic

In this report by It’s Not Healthy, we analyze the main vaccines that exist globally, their origin, their financing, aspects related to intellectual property, purchase agreements and their different prices. We show […]
01/06/2021

La vacuna: un bien público global para afrontar una pandemia

En este informe de No es Sano analizamos las principales vacunas que existen a nivel global, su origen, su financiación, aspectos relativos a la propiedad intelectual, los acuerdos de compra y sus […]
10/06/2020

Proposals to ensure access to vaccines, medicines and medical supplies

At the beginning of the COVID-19 pandemic, the It’s Not Healthy campaign sent this document to the Government and political parties with a package of proposals on pharmaceutical policy that entails a […]
10/06/2020

Propuestas para asegurar el acceso a vacunas, medicamentos y material sanitario

En los inicios de la pandemia de la COVID-19, la campaña No es Sano envió al Gobierno y a los partidos políticos este documento con un paquete de propuestas sobre política farmacéutica […]
10/04/2020

Public investment in R&D in COVID-19

Informe de Salud por Derecho analyzes public investment in research and development of drugs and vaccines during the first months of the COVID-19 pandemic. Likewise, it includes a series of recommendations to […]
10/04/2020

La inversión pública en la I+D en COVID-19

Informe de Salud por Derecho analiza la inversión pública en investigación y desarrollo de fármacos y vacunas durante los primeros meses de la pandemia de la COVID-19. Así mismo, recoge una serie […]